
Following FDA Meeting, Testing of Possible Myelofibrosis Drug to Continue
According to a story from BioSpace, CTI BioPharma Corp. has recently concluded an End of Phase 2A meeting with representatives from the US Food and Drug Administration (FDA). This meeting…